Herpes

Science Translational Medicine Publication: Innovative Molecules´ Drug Candidate Affects Recurrent Herpes Simplex Virus Infections

Retrieved on: 
Wednesday, June 16, 2021
Medical specialties, Sexually transmitted diseases and infections, Virology, Herpes, Clinical medicine, Viral diseases, Herpes simplex virus, Herpes simplex, Herpes labialis, Genital herpes, HSV-2, Sexually transmitted infection

The study entitled A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections was conducted by a team of researchers from the U.S. and Germany and was published today in Science Translational Medicine .

Key Points: 
  • The study entitled A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections was conducted by a team of researchers from the U.S. and Germany and was published today in Science Translational Medicine .
  • IM-250 is devoid of off-target activity observed with other anti-HSV drugs and of potential metabolites of previous drug candidates targeting helicase-primase.
  • At least 50 % of the population is infected with Herpes simplex virus type 1 (HSV-1), mostly herpes labialis, whereas approx.
  • 25% of the population is infected withHerpes simplex virus type 2 (HSV-2), mostly genital herpes, a sexually transmitted infection/disease.

2021 Epidemiology Forecast for the Global Herpes Market to 2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 4, 2021
Health, General Health, Medical specialties, Sexually transmitted diseases and infections, Medicine, Virology, Viral diseases, Biology of bipolar disorder, Herpes simplex, Herpes, Disease

b'The "Global Herpes Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report provides Herpes epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Herpes Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report provides Herpes epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Herpes patients, history of the disease at the population level (Herpes prevalence, Herpes incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Herpes patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Herpes market sizing, assessing market potential, and developing drug forecast models\nIdentify Herpes patients segments through age groups, gender, and disease sub-types\n'

Candel Therapeutics Completes Enrollment in Phase 1 Clinical Trial of CAN-2409 in Combination with Opdivo® (nivolumab) for the Treatment of High-Grade Gliomas

Retrieved on: 
Thursday, April 22, 2021
Research, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Clinical medicine, Medicine, Cancer, Cancer immunotherapy, Virotherapy, Herpes, Oncology, Cancer treatments, Immunotherapy, Valaciclovir, Chemotherapy, Checkpoint inhibitor

\xe2\x80\x9cWith a significant number of patients affected each year and limited treatment options available, there remains a critical need for effective therapies in high-grade glioma.

Key Points: 
  • \xe2\x80\x9cWith a significant number of patients affected each year and limited treatment options available, there remains a critical need for effective therapies in high-grade glioma.
  • HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells.
  • Combination activity with standard of care radiation therapy, surgery, immune checkpoint inhibitors\n(ICI) and chemotherapy has already been shown in several preclinical and clinical settings.
  • Our approach combines an in-depth knowledge of viral immunotherapy with extensive clinical experience across a wide range of indications.

Rational Vaccines Licenses Promising Technology from Louisiana State University

Retrieved on: 
Monday, April 5, 2021
Sexually transmitted diseases and infections, Medical specialties, Herpes, Virology, Microbiology, Viral diseases, Biology of bipolar disorder, Herpes simplex, HSV-2, Genital herpes, HSV, Vaccine

CEO says licensing of VC2 is a significant milestone for Rational Vaccines as they strive to eradicate the herpes virus.

Key Points: 
  • CEO says licensing of VC2 is a significant milestone for Rational Vaccines as they strive to eradicate the herpes virus.
  • "We are so very excited about adding this incredible science to the Rational Vaccines arsenal and partnering with Louisiana State University in the fight against HSV," said Rational CEO Agustin Fernandez.
  • The VC2 vaccines target facial, ocular and genital herpes caused by HSV-1, but may also provide protection against genital herpes causes by HSV-2.
  • Based in Cambridge, MA, Rational Vx is also joining the battle against COVID-19 with a serological assay currently in development, and a future COVID-19 vaccineplanned.

Rational Vaccines names Dr. Konstantin Kousoulas Vice President of Scientific Affairs

Retrieved on: 
Friday, February 26, 2021
Medical specialties, Virology, Viral diseases, Sexually transmitted diseases and infections, Microbiology, Herpes, Biology of bipolar disorder, Herpes simplex, HSV-2, Herpes virus, Herpesviridae, Vaccine

CAMBRIDGE, Mass., Feb. 26, 2021 /PRNewswire/ --Leading virologist Konstantin "Gus" Kousoulas joined Rational Vaccines as vice president of Scientific Affairs where he will work to further the company's core mission of eradicating the world of the herpes simplex virus (HSV), the company announced today.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 26, 2021 /PRNewswire/ --Leading virologist Konstantin "Gus" Kousoulas joined Rational Vaccines as vice president of Scientific Affairs where he will work to further the company's core mission of eradicating the world of the herpes simplex virus (HSV), the company announced today.
  • His addition to the team brings us one step closer to our goal of eradicating the Herpes pandemic."
  • Kousoulas' research focuses primarily on the molecular biology and the immunopathogenesis of human herpes viruses.
  • Rational Vaccines develops rationally engineered, live attenuated viral immunotherapeutic and prophylactic vaccine candidates, particularly focused on combating all diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections.

Herpesyl Review: Get Rid of Herpes Virus with This Supplement

Retrieved on: 
Tuesday, January 12, 2021
Medical specialties, Sexually transmitted diseases and infections, Virology, Herpes, Clinical medicine, Viral diseases, Biology of bipolar disorder, Herpes simplex, Genital herpes, Herpetic gingivostomatitis, Infection, Herpes simplex research

NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Herpesyl is a natural supplement that helps people to fight herpes symptoms.

Key Points: 
  • NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Herpesyl is a natural supplement that helps people to fight herpes symptoms.
  • There are two types of Herpes infection, genital Herpes, and Oral Herpes.
  • According to the manufacturer of Herpesyl , it is a perfect blend of natural ingredients, which makes it a potent supplement like drugs used to treat Herpes.
  • Herpesyl is an effective supplement that works best for herpes outbreaks to treat the inner cause of herpes infection.

Herpesyl Review: Get Rid of Herpes Virus with This Supplement

Retrieved on: 
Tuesday, January 12, 2021
Medical specialties, Sexually transmitted diseases and infections, Virology, Herpes, Clinical medicine, Viral diseases, Biology of bipolar disorder, Herpes simplex, Genital herpes, Herpetic gingivostomatitis, Infection, Herpes simplex research

NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Herpesyl is a natural supplement that helps people to fight herpes symptoms.

Key Points: 
  • NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Herpesyl is a natural supplement that helps people to fight herpes symptoms.
  • There are two types of Herpes infection, genital Herpes, and Oral Herpes.
  • According to the manufacturer of Herpesyl , it is a perfect blend of natural ingredients, which makes it a potent supplement like drugs used to treat Herpes.
  • Herpesyl is an effective supplement that works best for herpes outbreaks to treat the inner cause of herpes infection.

HSV Eraser Review: PDF eBook For Permanently Eliminate the Herpes Virus from One's Body

Retrieved on: 
Tuesday, December 29, 2020
Sexually transmitted diseases and infections, Medical specialties, Virology, Viral diseases, Herpes, Infectious diseases, Biology of bipolar disorder, Herpes simplex, HSV-2, HSV, Herpes simplex research

Readers should know that there are two types of the herpes virus, HSV1, and HSV2.

Key Points: 
  • Readers should know that there are two types of the herpes virus, HSV1, and HSV2.
  • Now, the HSV Eraser Review is a 21-day program kit that helps in the treatment of herpes .
  • The more conventional treatment doesn't permanently wipe away the virus from the body.
  • On the other hand, HSV Eraser Reviewis a cure that will help users to get rid of the virus permanently.

HSV Eraser Review: PDF eBook For Permanently Eliminate the Herpes Virus from One's Body

Retrieved on: 
Tuesday, December 29, 2020
Sexually transmitted diseases and infections, Medical specialties, Virology, Viral diseases, Herpes, Infectious diseases, Biology of bipolar disorder, Herpes simplex, HSV-2, HSV, Herpes simplex research

Readers should know that there are two types of the herpes virus, HSV1, and HSV2.

Key Points: 
  • Readers should know that there are two types of the herpes virus, HSV1, and HSV2.
  • Now, the HSV Eraser Review is a 21-day program kit that helps in the treatment of herpes .
  • The more conventional treatment doesn't permanently wipe away the virus from the body.
  • On the other hand, HSV Eraser Reviewis a cure that will help users to get rid of the virus permanently.

Global Herpes Treatment Market to Grow by $ 677 Million During 2020-2024 | Highlights Key Segments and Regions of Growth | Technavio

Retrieved on: 
Friday, December 4, 2020
Health, Pharmaceutical, Medical specialties, Virology, Viral diseases, Sexually transmitted diseases and infections, Chickenpox, Biology of bipolar disorder, Herpes simplex, Shingles, Herpes, Neonatal herpes simplex

This is due to the rising prevalence rate of herpes zoster and expected drug launches for the treatment of the condition.

Key Points: 
  • This is due to the rising prevalence rate of herpes zoster and expected drug launches for the treatment of the condition.
  • Also, factors such as the rising number of immunocompromised people and the increasing older population are contributing to the growth of the segment.
  • Factors such as the high prevalence rate of herpes infection, increased awareness, and entry of new players are fostering the growth of the herpes treatment market in Asia.
  • Market growth in this region will be faster than the growth of the market in other regions.